1. |
- Germanakos, P., et al.
(författare)
-
HAAPIE 2024 : 9th International Workshop on Human Aspects in Adaptive and Personalized Interactive Environments
- 2024
-
Ingår i: UMAP Adjunct '24: Adjunct Proceedings of the 32nd ACM Conference on User Modeling, Adaptation and Personalization. - : ACM Digital Library. - 9798400704666 ; , s. 362-364
-
Konferensbidrag (refereegranskat)abstract
- Nowadays, the profound digital transformation has upgraded the role of the computational system into an intelligent multidimensional communication medium that creates new opportunities, competencies, models and processes. The need for human-centered adaptation and personalization is even more recognizable since it can offer hybrid solutions that could adequately support the rising multi-purpose goals, needs, requirements, activities and interactions of users. The HAAPIE workshop1 embraces the essence of the "human-machine co-existence"and brings together researchers and practitioners from different disciplines to present and discuss a wide spectrum of related challenges, approaches and solutions. In this respect, the ninth edition of HAAPIE includes 4 long papers and 2 short papers.
|
|
2. |
|
|
3. |
- Germanakos, P., et al.
(författare)
-
HAAPIE 2023 : 8th International Workshop on Human Aspects in Adaptive and Personalized Interactive Environments
- 2023
-
Ingår i: UMAP '23 Adjunct. - : Association for Computing Machinery (ACM). - 9781450398916 ; , s. 302-304
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- Nowadays, the profound digital transformation has upgraded the role of the computational system into an intelligent multidimensional communication medium that creates new opportunities, competencies, models and processes. The need for human-centered adaptation and personalization is even more recognizable since it can offer hybrid solutions that could adequately support the rising multi-purpose goals, needs, requirements, activities and interactions of users. The HAAPIE workshop1 embraces the essence of the "human-machine co-existence"and brings together researchers and practitioners from different disciplines to present and discuss a wide spectrum of related challenges, approaches and solutions. In this respect, the seventh edition of HAAPIE includes 2 long papers and 5 short papers.
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
- Germanakos, P., et al.
(författare)
-
HAAPIE 2022 : 7th International Workshop on Human Aspects in Adaptive and Personalized Interactive Environments
- 2022
-
Ingår i: UMAP 2022. - New York, NY, USA : Association for Computing Machinery (ACM). - 9781450392327 ; , s. 314-316
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- Nowadays, the profound digital transformation has upgraded the role of the computational system into an intelligent multidimensional communication medium that creates new opportunities, competencies, models and processes. The need for human-centered adaptation and personalization is even more recognizable since it can offer hybrid solutions that could adequately support the rising multi-purpose goals, needs, requirements, activities and interactions of users. The HAAPIE workshop1 embraces the essence of the "human-machine co-existence"and brings together researchers and practitioners from different disciplines to present and discuss a wide spectrum of related challenges, approaches and solutions. In this respect, the seventh edition of HAAPIE includes 5 long papers and 2 short papers.
|
|
9. |
- Moorkens, E, et al.
(författare)
-
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
- 2021
-
Ingår i: Frontiers in pharmacology. - : Frontiers Media SA. - 1663-9812. ; 11, s. 591134-
-
Tidskriftsartikel (refereegranskat)abstract
- Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of this paper is to provide a European overview of (list) prices of originator adalimumab, before and after loss of exclusivity; to report changes in the reimbursement status of adalimumab products; and discuss relevant policy measures.Methods: Experts in European countries received a survey consisting of three parts: 1) general financing/co-payment of medicines, 2) reimbursement status and prices of originator adalimumab, and availability of biosimilars, and 3) policy measures related to the use of adalimumab.Results: In May 2019, adalimumab biosimilars were available in 24 of the 30 countries surveyed. Following introduction of adalimumab biosimilars, a number of countries have made changes in relation to the reimbursement status of adalimumab products. Originator adalimumab list prices varied between countries by a factor of 2.8 before and 4.1 after loss of exclusivity. Overall, list prices of originator adalimumab decreased after loss of exclusivity, although for 13 countries list prices were unchanged. When reported, discounts/rebates on originator adalimumab after loss of exclusivity ranged from 0% to approximately 26% (Romania), 60% (Poland), 80% (Denmark, Italy, Norway), and 80–90% (Netherlands), leading to actual prices per pen or syringe between €412 (Finland) and €50 – €99 (Netherlands). To leverage competition following entry of biosimilar adalimumab, only a few countries adopted measures specifically for adalimumab in addition to general policies regarding biosimilars. In some countries, a strategy was implemented even before loss of exclusivity (Denmark, Scotland), while others did not report specific measures.Conclusion: Even though originator adalimumab is the highest selling product in the world, few countries have implemented specific policies and practices for (biosimilar) adalimumab. Countries with biosimilars on the market seem to have competition lowering list or actual prices. Reported discounts varied widely between countries.
|
|
10. |
|
|